Neurophysiology

, Volume 49, Issue 4, pp 283–287 | Cite as

Effects of Beta-Adrenergic Blockade on Diabetes-Induced Neurobehavioral Alterations in Mice

Article
  • 19 Downloads

Neurobehavioral activities were estimated in three groups of male albino mice using the open field, elevated plus maze, light/dark board, and hole-board tests. The control group included intact animals, while alloxan-induced diabetes was evoked in the other two groups (single i.p. injection of 120 mg/kg alloxan). In the third group, a nonspecific beta-adrenoreceptor antagonist, propranolol, was i.p. injected (40 mg/kg) before the induction of diabetes. In diabetic mice, all neurobehavioral indices tested in the four above-mentioned tests were significantly (P< 0.05) smaller than those in the control group. The frequencies of rearings and grooming episodes in the open field, number of entries into the open arms and time spent in these arms in the elevated plus maze test, and number of head dips in the hole-board test demonstrated the most intense drops (more than twofold). Pretreatment with propranolol provided significant (P < 0.05) normalization of all neurobehavioral indices in diabetic mice; such normalization with respect to the locomotion intensity, frequency of grooming, time spent in the open arms, and both indices in the light/dark board was nearly complete. Thus, diabetes in the animal model used is accompanied by the development of the state of abnormally high anxiety. The activity of the betaadrenergic system is noticeably involved in the formation of this state; pharmacological blocking of beta-adrenoreceptors provides significant anxiolytic effects.

Keywords

alloxan-induced diabetes neurobehavioral indices behavioral testing anxiety betaadrenoreceptors propranolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. D. Mooradian, “Pathophysiology of central nervous system complications in diabetes mellitus,” Clin. Neurosci., 4, No. 6, 322-326 (1997).PubMedGoogle Scholar
  2. 2.
    A. M. Jacobson, G. Musen, C. M. Ryan, et al., “Long term effects of diabetes and its treatment on cognitive function,” New Engl. J. Med., 356, 1842-1852 (2007).CrossRefPubMedGoogle Scholar
  3. 3.
    A. Ott, R. P. Stalk, A. Hofman, et al., “Association of diabetes mellitus and dementia: the Rotterdam study,” Diabetologica, 39, 1392-1399 (1966).CrossRefGoogle Scholar
  4. 4.
    C. T. Kodhl, D. T. Franc, J. P. Rao, et al., “Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlates with reduced neurocognitive function,” Diabetes, 57, 3083-3089 (2008).CrossRefGoogle Scholar
  5. 5.
    B. M. Lobnig, O. Kromeke, C. Optenhostert-Porst, and O. T Wolf, “Hippocampal volume and cognitive performance in long-standing type 1 diabetic patients without microvascular complications,” Diabetic Med., 33, 32-39 (2006).CrossRefGoogle Scholar
  6. 6.
    G. Musen, C. M. Ryan, D. C. Jimerson, et al., “Effect of type 1 diabetes on gray matter density as measured by Voxel-based morphometry,” Diabetes, 55, 326-333 (2006).CrossRefPubMedGoogle Scholar
  7. 7.
    L. M. Amy, L. C. Jonathan, and J. E. Bay, “Reconsolidation of appetitive memory for both natural and drug reinforcement is dependent on β adrenergic receptors,” Learning Memory, 15, 88-92 (2008).CrossRefGoogle Scholar
  8. 8.
    A. Jangre, A. K. Datusalia, and S. S. Sharma, “Reversal of neurobehavioral and neurochemical alterations in STZ-induced diabetic rats by FeTMPyP, a peroxynitrite decomposition catalyst and 1,5-isoquinolinediol a poly(ADP-ribose) polymerase inhibitor,” Neurol. Res., 36, No. 7, 619-626 (2014).CrossRefGoogle Scholar
  9. 9.
    M. Bjorkland, I. Scheinin, T. Heikinen, et al., “Spatial memory improvement by an alpha-2 adrenoceptor agonist dexmedetomidine is not mediated through alpha 2c adrenoceptor,” Prog. Neuropsychopharmacol. Biol. Psychiat., 25, 1539-1554 (2001).CrossRefGoogle Scholar
  10. 10.
    S. Pellow, P. Chopin, S. E. File, and M. Brilley, “Validation of open/closed arm entries in an elevated plus maze as a measure of anxiety in the rat,” J. Neurosci., 14, 149-167 (1985).Google Scholar
  11. 11.
    S. Pellow and S. File, “Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus maze: A novel test of anxiety in the rat,” Pharmacol. Biochem. Behav., 24, 526-530 (1986).Google Scholar
  12. 12.
    C. Torres and M. D. Escarabajal, “Validation of a behavioral recording automated system in the elevated plus maze test,” Life Sci., 70, 1751-1762 (2002).CrossRefPubMedGoogle Scholar
  13. 13.
    A. B. Grisby, R. J. Anderson, K. E. Freeland, et al., “Diabetes and anxiety,” J. Psychosom. Res., 53, No. 6, 103-162 (2002).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Physiology, College of MedicineUniversity of IbadanIbadanNigeria

Personalised recommendations